Literature DB >> 29866885

Hematopoietic stem cells made BETter by inhibition.

Ludovica Marando1,2,3, Brian J P Huntly4,2,3.   

Abstract

Mesh:

Year:  2018        PMID: 29866885      PMCID: PMC6058785          DOI: 10.3324/haematol.2018.193706

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  22 in total

Review 1.  How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers.

Authors:  Sean D Taverna; Haitao Li; Alexander J Ruthenburg; C David Allis; Dinshaw J Patel
Journal:  Nat Struct Mol Biol       Date:  2007-11-05       Impact factor: 15.369

2.  BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

Authors:  Jake E Delmore; Ghayas C Issa; Madeleine E Lemieux; Peter B Rahl; Junwei Shi; Hannah M Jacobs; Efstathios Kastritis; Timothy Gilpatrick; Ronald M Paranal; Jun Qi; Marta Chesi; Anna C Schinzel; Michael R McKeown; Timothy P Heffernan; Christopher R Vakoc; P Leif Bergsagel; Irene M Ghobrial; Paul G Richardson; Richard A Young; William C Hahn; Kenneth C Anderson; Andrew L Kung; James E Bradner; Constantine S Mitsiades
Journal:  Cell       Date:  2011-09-01       Impact factor: 41.582

3.  BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia.

Authors:  Jae-Seok Roe; Fatih Mercan; Keith Rivera; Darryl J Pappin; Christopher R Vakoc
Journal:  Mol Cell       Date:  2015-05-14       Impact factor: 17.970

4.  Selective inhibition of tumor oncogenes by disruption of super-enhancers.

Authors:  Jakob Lovén; Heather A Hoke; Charles Y Lin; Ashley Lau; David A Orlando; Christopher R Vakoc; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2013-04-11       Impact factor: 41.582

5.  BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia.

Authors:  Christopher J Ott; Nadja Kopp; Liat Bird; Ronald M Paranal; Jun Qi; Teresa Bowman; Scott J Rodig; Andrew L Kung; James E Bradner; David M Weinstock
Journal:  Blood       Date:  2012-08-17       Impact factor: 22.113

6.  Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.

Authors:  Sandy Amorim; Anastasios Stathis; Mary Gleeson; Sunil Iyengar; Valeria Magarotto; Xavier Leleu; Franck Morschhauser; Lionel Karlin; Florence Broussais; Keyvan Rezai; Patrice Herait; Carmen Kahatt; François Lokiec; Gilles Salles; Thierry Facon; Antonio Palumbo; David Cunningham; Emanuele Zucca; Catherine Thieblemont
Journal:  Lancet Haematol       Date:  2016-03-18       Impact factor: 18.959

7.  BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD.

Authors:  Warren Fiskus; Sunil Sharma; Jun Qi; Bhavin Shah; Santhana G T Devaraj; Christopher Leveque; Bryce P Portier; Swaminathan Iyer; James E Bradner; Kapil N Bhalla
Journal:  Mol Cancer Ther       Date:  2014-07-22       Impact factor: 6.261

8.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.

Authors:  Mark A Dawson; Rab K Prinjha; Antje Dittmann; George Giotopoulos; Marcus Bantscheff; Wai-In Chan; Samuel C Robson; Chun-wa Chung; Carsten Hopf; Mikhail M Savitski; Carola Huthmacher; Emma Gudgin; Dave Lugo; Soren Beinke; Trevor D Chapman; Emma J Roberts; Peter E Soden; Kurt R Auger; Olivier Mirguet; Konstanze Doehner; Ruud Delwel; Alan K Burnett; Phillip Jeffrey; Gerard Drewes; Kevin Lee; Brian J P Huntly; Tony Kouzarides
Journal:  Nature       Date:  2011-10-02       Impact factor: 49.962

9.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.

Authors:  Johannes Zuber; Junwei Shi; Eric Wang; Amy R Rappaport; Harald Herrmann; Edward A Sison; Daniel Magoon; Jun Qi; Katharina Blatt; Mark Wunderlich; Meredith J Taylor; Christopher Johns; Agustin Chicas; James C Mulloy; Scott C Kogan; Patrick Brown; Peter Valent; James E Bradner; Scott W Lowe; Christopher R Vakoc
Journal:  Nature       Date:  2011-08-03       Impact factor: 49.962

10.  Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia.

Authors:  M A Dawson; E J Gudgin; S J Horton; G Giotopoulos; E Meduri; S Robson; E Cannizzaro; H Osaki; M Wiese; S Putwain; C Y Fong; C Grove; J Craig; A Dittmann; D Lugo; P Jeffrey; G Drewes; K Lee; L Bullinger; R K Prinjha; T Kouzarides; G S Vassiliou; B J P Huntly
Journal:  Leukemia       Date:  2013-11-13       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.